Table 5.
Summary of data used for the meta-analysis of the association between prenatal estrogenic agents and cryptorchidism.
| Cases
|
Controls
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| References | Design | Agent | Location | E | NE | E | NE | RR (95% CI) | SE | Weight | Quality score |
| Beard et al. 1984 | Case–control | Estrogenic drugs | Minnesota, USA | 9 | 104 | 15 | 211 | 2.20 (0.70–7.20) | 0.47 | 4.60 | 34 |
| Bhatia et al. 2005 | Case–control | DDT | California, USA | 11 | 32 | 42 | 117 | 0.95 (0.43–2.07) | 0.39 | 6.65 | 41 |
| Depue 1988 | Case–control | Estrogenic drugs | United States | 5 | 380 | 3 | 765 | 5.15 | 1.01 | 0.99 | 29 |
| Harlap et al. 1985 | Cohort | Oral contraceptives | North Carolina, USA | 6 | 196 | 844 | 27,595 | 1.10 (0.10–3.90) | 0.42 | 5.78 | 36 |
| McBride et al. 1991 | Case–control | Oral contraceptives | British Columbia, Canada | 18 | 226 | 34 | 454 | 1.10 | 0.31 | 10.50 | 38 |
| Vessey et al. 1983 | Clinical trial | DES | United Kingdom | 6 | 6 | 138 | 126 | 0.91 | 0.58 | 3.00 | 18 |
Abbreviations: E, exposed; NE, nonexposed.